Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. Some patients with HCC are diagnosed with macrovascular invasion (MVI), which is associated with a poorer prognosis. In Taiwan, sorafenib is the first-line therapy for patients with advanced HCC. However, the ef...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Che-Jui Chang, Wei-Fan Hsu, Long-Bin Jeng, Hsueh-Chou Lai, Shih-Chao Hsu, Te-Hung Chen, Hung-Wei Wang, Cheng-Yuan Peng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2023-11-01
coleção:	Current Oncology
Assuntos:	sorafenib hepatocellular carcinoma macrovascular invasion post-operation
Acesso em linha:	https://www.mdpi.com/1718-7729/30/12/737
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!